These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32104448)

  • 1. Effect of raw material variability of glipizide on the
    Zhao C; Jin C; Gao H; Wang L; Liu H; He Z
    Asian J Pharm Sci; 2019 Mar; 14(2):165-173. PubMed ID: 32104448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of excipients on the particle size of precipitated pioglitazone in the gastrointestinal tract: impact on bioequivalence.
    Sugita M; Kataoka M; Sugihara M; Takeuchi S; Yamashita S
    AAPS J; 2014 Sep; 16(5):1119-27. PubMed ID: 25070482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring Bismuth Oxide Particle Size and Morphology in Film-Coated Tablets.
    Fertaki S; Bagourakis G; Orkoula M; Kontoyannis C
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient Evaluation of In Vivo Performance in Human for Generic Formulation by Novel Dissolution-Absorption Prediction (DAP) Workflow.
    Onishi M; Tagawa K; Jiko M; Koike K; Maruyama M; Hashizume H; Imagaki K; Higaki K
    Pharm Res; 2022 Sep; 39(9):2203-2216. PubMed ID: 35836039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets.
    Pepin XJ; Flanagan TR; Holt DJ; Eidelman A; Treacy D; Rowlings CE
    Mol Pharm; 2016 Sep; 13(9):3256-69. PubMed ID: 27438964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the In-Vitro Dissolution Permeation Systems 1 (IDAS1) as a potential tool to monitor for unexpected changes in generic medicaments in poorly regulated markets.
    Rodriguez N; Grosso M; Galvez B; Calderon G; Lau L; Turner VA; Hidalgo IJ
    Eur J Pharm Sci; 2021 Jun; 161():105791. PubMed ID: 33691154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing.
    Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Rome S; Schubert MA; Aerts L; De Beer T
    Eur J Pharm Biopharm; 2018 Jun; 127():92-103. PubMed ID: 29452241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of performance matrix for generic product equivalence of acyclovir topical creams.
    Krishnaiah YS; Xu X; Rahman Z; Yang Y; Katragadda U; Lionberger R; Peters JR; Uhl K; Khan MA
    Int J Pharm; 2014 Nov; 475(1-2):110-22. PubMed ID: 25089511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing API raw material variability during continuous twin-screw wet granulation.
    Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Vervaet C; De Beer T
    Int J Pharm; 2019 Apr; 561():265-273. PubMed ID: 30851387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
    Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
    J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization,
    Bedor DCG; Bedor NCTC; Neto JGP; José de Alencar Danda L; de Oliveira FM; de Oliveira GHO; Soares Sobrinho JL; Beyssac E; Castro WV; Santana DP
    Drug Dev Ind Pharm; 2021 May; 47(5):725-734. PubMed ID: 34038291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH.
    Zhu H; Chen X; Ahmed M; Wang Y; Liu Q; Uppoor RS; Kuemmel C; Mehta M
    Clin Transl Sci; 2019 Nov; 12(6):564-572. PubMed ID: 31169344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro and In Vivo Evaluation of Different Solid Dosage Forms Containing Captopril.
    Abdalrb GA; Mircioiu I; Amzoiu M; Belu I; Anuta V
    Curr Health Sci J; 2017; 43(3):214-219. PubMed ID: 30595878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules.
    Piscitelli DA; Bigora S; Propst C; Goskonda S; Schwartz P; Lesko LJ; Augsburger L; Young D
    Pharm Dev Technol; 1998 Nov; 3(4):443-52. PubMed ID: 9834946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient drug development of oseltamivir capsules based on process control, bioequivalence and PBPK modeling.
    Medeiros JJS; Costa TM; Carmo MP; Nascimento DD; Lauro ENC; Oliveira CA; Duque MD; Prado LD
    Drug Dev Ind Pharm; 2022 Apr; 48(4):146-157. PubMed ID: 35876070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of
    Zhang S; Fang M; Zhang Q; Li X; Zhang T
    Drug Dev Ind Pharm; 2019 Oct; 45(10):1646-1653. PubMed ID: 31342807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.